BPC-157 vs ipamorelin

BPC-157 and ipamorelin intersect with growth-hormone biology at different points. BPC-157 increased growth-hormone receptors in rat tendon cells; ipamorelin stimulated growth-hormone release in human exposure research. BPC-157 also improved rat tendon-repair measurements, while ipamorelin’s postoperative meal-tolerance trial left benefit uncertain. These studies do not establish which improves human injury recovery or whether combining them helps.

Research reviewed October 15, 2026. Educational information only.

Two sequences and different connections to growth hormone

BPC-157 is a synthetic fifteen-residue peptide with the sequence GEPPPGKPADDAGLV. FDA distinguishes its free base and acetate salt. Ipamorelin is the five-residue amidated peptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, including nonstandard amino-acid components and D-form residues. Its original experiments placed it in the growth-hormone secretagogue receptor system, now associated with the ghrelin receptor. These molecular identities matter when comparing studied preparations with products using the same names. FDA (2026), Raun et al. (1998).

Their connection to growth hormone involves two different measurements. BPC-157-exposed rat tendon cells produced more receptors for growth hormone. Ipamorelin exposure in healthy men caused an episode of growth-hormone release into blood. More receptors in a cell culture and more circulating hormone answer different biological questions; neither measurement alone establishes better recovery after a human injury. Chang et al. (2014), Gobburu et al. (1999).

The main differences

BPC-157 changed how cultured tendon cells responded to added hormone

Chang and colleagues isolated fibroblasts, connective-tissue cells, from male rat Achilles tendons and grew them in dishes. Compared with cultures receiving no BPC-157, exposed cells increased growth-hormone receptor RNA and protein over one to three days. The report describes increases reaching about sevenfold by day three under one condition. Subsequent experiments added growth hormone to the cells and found increased multiplication-related measurements and activation of JAK2, a protein that relays the receptor’s signal inside the cell. Chang et al. (2014).

This setup supplied growth hormone experimentally after BPC-157 exposure. The study did not test ipamorelin, demonstrate a rise in circulating growth hormone from BPC-157 or measure recovery of an injured person. Its useful finding is a change in the response of rat tendon cells to an added signal. A proposed combined treatment would need its own experiment measuring a meaningful outcome and harms.

The rat tendon study measured repaired-tissue function

In the 2003 Achilles experiment, researchers cut rat tendons and compared BPC-157 dissolved in saline with saline alone. Assessments through day fourteen included the force required to break the tissue, its response to stretching, a walking-derived functional index and microscopic structure. The BPC-157 groups had favorable mechanical, functional and structural findings compared with saline controls. The abstract supplies no numerical between-group force estimate or complete group counts. Staresinic et al. (2003).

This experiment reaches beyond a receptor measurement because it examines the tissue’s mechanical behavior after injury. Its surgical rat model still leaves human tendon recovery unresolved. It also used a specific preparation and route; the result does not establish the effectiveness of an oral, topical or combined commercial product.

Ipamorelin’s human studies measured hormone release and gut recovery

Gobburu and colleagues measured blood ipamorelin and growth hormone after short intravenous infusions in healthy men. The abstract describes eight men at each of five exposure levels without stating the total number of unique participants. Ipamorelin’s estimated terminal half-life was about two hours, while growth hormone peaked separately around 0.67 hours. The investigators measured acute hormone release and peptide exposure, without a strength, muscle-growth or injury-healing outcome. Gobburu et al. (1999).

The clinical test after bowel surgery asked whether ipamorelin would restore the ability to tolerate a solid meal sooner. Beck and colleagues enrolled 117 adults undergoing small- or large-bowel resection, with 114 in the main safety and efficacy populations. Median time from initial treatment to tolerating a standardized meal was 25.3 hours with intravenous ipamorelin and 32.6 hours with placebo. The earlier numerical time remained too uncertain to establish benefit (P=0.15); secondary efficacy analyses also did not establish group differences. This result leaves a possible effect unresolved rather than proving identical treatment effects. Beck et al. (2014).

BPC-157 has a different, limited human bowel report. FDA’s account of a two-week randomized ulcerative-colitis meeting abstract describes 53 randomized participants and 46 completers receiving a rectal preparation or placebo enema. The combined disease-activity score fell by 3.2 versus 1.6 points, but the between-group 95% confidence interval included zero (−4.84 to 1.62). FDA judged the incomplete reporting inadequate to establish effectiveness. Ulcerative-colitis activity and postoperative meal tolerance are different outcomes in different populations. FDA (2026).

Blood persistence depends on the compound, species and assay

The BPC-157 exposure paper measured intact peptide in rats and beagle dogs after intravenous and intramuscular administration. Intravenous elimination estimates were 15.2 minutes in the rat analysis and 5.27 ± 2.25 minutes in six dogs. Rat sampling used separate animals at successive times. Separate radioactive-tracer experiments followed peptide-derived material, including fragments and metabolites, so persistent radioactivity did not establish persistence of intact BPC-157. He et al. (2022).

Ipamorelin’s roughly two-hour estimate came from human intravenous research. Comparing it numerically with an animal BPC-157 half-life would mix species and study designs. Neither value measures delivery to a human tendon or determines how long a downstream tissue response lasts. These studies do not provide an exposure model for a combined product.

Clinical studies leave recovery benefits and long-term safety unresolved

In ipamorelin’s postoperative trial, treatment-emergent adverse events occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group. Bowel-resection patients have substantial background illness and procedural risks. FDA’s detailed review describes serious events including two deaths after postoperative complications and states that their relationship to ipamorelin was unclear. A lower overall event percentage cannot establish a long-term safety advantage, especially across different routes or products. Beck et al. (2014), FDA (2024).

FDA also identifies peptide-impurity, aggregation and immune-reaction concerns and major clinical safety gaps for the proposed compounded substances. The small, short-term rectal BPC-157 reports do not characterize long-term injectable use. Ipamorelin’s relative hormone selectivity in pigs likewise cannot establish freedom from human adverse effects. The source-specific observations describe biological leads and limited clinical tests; no direct trial identified here establishes a human injury-recovery advantage or a useful BPC-157–ipamorelin combination. FDA (2026).

Frequently asked questions

Profiles and related reading

References

1. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, Aralica G, Zarkovic N, Borovic S, Srdjak M, Hajdarevic K, Kopljar M, Batelja L, Boban-Blagaic A, Turcic I, Anic T, Seiwerth S, Sikiric P. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of orthopaedic research : official publication of the Orthopaedic Research Society. 2003;21(6):976–983. doi:10.1016/S0736-0266(03)00110-4. PMID:14554208.

   After rat Achilles tendons were cut, BPC-157 increased the force required to break repaired tissue and improved walking-related and tissue-structure measurements compared with saline controls through fourteen days. The accessible abstract supplies no numerical between-group mechanical estimate.

2. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (Basel, Switzerland). 2014;19(11):19066–19077. doi:10.3390/molecules191119066. PMID:25415472.

   In rat Achilles-tendon fibroblasts, BPC-157 increased growth-hormone receptors. Subsequent added growth hormone increased cell multiplication and signaling through JAK2, a protein relaying growth-hormone receptor signals; circulating hormone and patient recovery were not measured.

3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. 1998;139(5):552–561. doi:10.1530/eje.0.1390552. PMID:9849822.

   Ipamorelin stimulated growth hormone in cell and animal systems. Its relative selectivity concerning ACTH, a pituitary signal to the adrenal glands, and cortisol, a stress-related hormone, was tested in pigs and is not a comprehensive human safety result.

4. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research. 1999;16(9):1412–1416. doi:10.1023/a:1018955126402. PMID:10496658.

   Healthy men receiving short intravenous infusions showed an ipamorelin half-life near two hours and a separate growth-hormone peak around 0.67 hours. The abstract reports eight men per exposure level without a unique participant total.

5. Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease. 2014;29(12):1527–1534. doi:10.1007/s00384-014-2030-8. PMID:25331030.

   In adults after bowel resection, median solid-meal tolerance occurred earlier numerically with ipamorelin than placebo, but the comparison remained uncertain. The multicenter blinded trial enrolled 117, with 114 in its main analyses.

6. He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in pharmacology. 2022;13:1026182. doi:10.3389/fphar.2022.1026182. PMID:36588717.

   Separate intact-peptide and radioactive-tracer experiments in rats and dogs showed rapid BPC-157 disappearance from plasma. Persistent radioactivity could represent breakdown products.

7. U.S. Food and Drug Administration. FDA Briefing Document: BPC-157-Related Bulk Drug Substances (BPC-157 free base and BPC-157 acetate). Pharmacy Compounding Advisory Committee, July 23–24, 2026.

   FDA distinguishes BPC-157 free base and acetate and finds inadequate clinical safety information. Its account of a small ulcerative-colitis abstract preserves an uncertain between-group disease-score difference.

8. U.S. Food and Drug Administration. Ipamorelin-related bulk drug substances evaluation. Briefing document for the October 29, 2024 Pharmacy Compounding Advisory Committee meeting.

   FDA describes formulation and immune-reaction concerns and serious postoperative events, including two deaths whose relationship to ipamorelin was unclear.

9. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Official agency webpage accessed October 15, 2026.

   FDA identifies immune-response, peptide-impurity and characterization concerns for proposed compounded BPC-157 and ipamorelin products. Its ipamorelin account includes serious events and deaths after intravenous use, with insufficient safety information for some other injectable routes.